{"name":"NeuroSense Therapeutics Ltd.","slug":"neurosense-therapeutics-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"PrimeC","genericName":"PrimeC","slug":"primec","indication":"Immune support and antioxidant supplementation","status":"marketed"}]}],"pipeline":[{"name":"PrimeC","genericName":"PrimeC","slug":"primec","phase":"marketed","mechanism":"PrimeC is a nutritional supplement formulation designed to support immune and antioxidant function through a combination of vitamins and micronutrients.","indications":["Immune support and antioxidant supplementation"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxQRHJtakxvdkRYZ3J2azgyVWJiMVJpdDNZSFBQbEFfakVCcjZ0dUsydlVOMTlxa2pFdUdVengtendsdmJ2UG9nYzB5aVBJc1pYMmJwbnVkeTdlZ0xEMDRVVVBrYnFrN1lsNmo4VGlKdkdCSnV0c3VkdzlmRFluXzgtbmVNQURBNFpKa00tZDlWeXBod3hLR3ExTmpLbUxRTGFkMThDV0FmMk54VHJpeEhWbzRoSEhXVUlsYi1Ca2QyV3dPbWxvV0ZqMGFqbnN4Rk5Wd3N6ZUZ0dVR1MGpMdzF6eFhLN1l2a1MxbnFock1VU0ZMY0RHRTBHUmVB?oc=5","date":"2026-04-02","type":"trial","source":"Barchart.com","summary":"Motor Neuron Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 180+ Key Companies | DelveInsight - Barchart.com","headline":"Motor Neuron Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 180+ Key Companies | DelveIn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOMWdGNzl2MzVxdTJGTEVGUVoyaWZjWEV6dFBjbGF4d3AyTnNPdlhDNU9TRnJ0aHJLdFk0anoyam9ZbC1QanNKOTd0cjRUNW10M2R2Zk81TXRKVncyc2RJbUx0ZkY2REJaWmEtdk81c0lCaXd2b21pWmg4OGNwbi1zY09tdjJxTVFSS2phNy13SWhRVUhTYW96NmNZU2JqLUt6Z3N0dWRFUVJLczZuaGJkbG4zZTdkQlRDR3lHV1ZGaDVGd1NMLWVhOHNtTm9uUFJzblMwMktWZ3VtRDkzRk9qQloxdkotTC01SVItOTNIS2xBVTljamNZ?oc=5","date":"2026-04-01","type":"trial","source":"Barchart.com","summary":"Alzheimer’s Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 200+ Key Companies | DelveInsight - Barchart.com","headline":"Alzheimer’s Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 200+ Key Companies | DelveIns","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxQTnZsUVk4YWRseWN2SlFvOW9zcV9nRnVCYURsWWJwTEliUG1PSzl4bXNiVUQ1YU4tMmdPNC13cmtHWWhaUzhCOGhBbVhIbENGNkJsU0FXZ3RySk9yLUpSR0FScjdmczIzVmdQYUFNZ2xEYTcyRXZKcTdCSlV3cHkwRkZWcXpUdEhfVWFDSXR0LXhOUmk4TWMzOGZlaXNmaEExVlZsd1NNTHBfOXlkeDlYUS1ZUS0xRThGZ0JqRWk1c0MwT2tkc210S2NYVDFYWE16SG9Jb1NmTGQzMDNZbjRwckFuT0pFZw?oc=5","date":"2025-09-10","type":"pipeline","source":"prnewswire.com","summary":"NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons - prnewswire.com","headline":"NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE1tYmxJbEVkekpqdEVpM3ItTUVzZkxUay0yNy1BT2Y2QUxwTmJhczhFeDkya2hTcXM1QUZieHlaWGZBMWV5T3BGTGZWajg2aFpLNW1ITHVqZUljUEc3eGtpcjVqNEIxajdlcVUycVpHU0RnVkl5WUQwLW53?oc=5","date":"2025-05-12","type":"pipeline","source":"Yahoo Finance","summary":"Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights - Yahoo Finance","headline":"Why This Nano-Cap Stock Might Skyrocket To $14, Per Analyst Insights","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiSEFVX3lxTE54V2RiQm5FRFZlYmtMV0ZsdGlqQ2Z2RXJTRmpSeEFheUpxLUZhaTF0eFNidl8zaWdkd3VjQThPQnFMOWdBTDBXcg?oc=5","date":"2025-05-07","type":"pipeline","source":"Intellectia AI","summary":"NRSN Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI","headline":"NRSN Stock: Price, Forecast, Financials & AI Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxNbzcwN0VNdVBlcFQwbGNBempTQ2pEMVBJQzRTTlU2Y25JQXNHWmwzVGpMMzJDc3BjdzRkR0huXzNSZTlBRDA2NTBWWUNDVHdEdDUyRUNNTFZWMGMtMm5iUkI5Q0pSUm1mVnNJeTdwWDFWY0RHZFM2R09WYzJiam5LSnh3MlUwb3JJNTJNalNHcm51SXRlTEtLVXkxSUlaeDEyd25JMTA2UWpGUi10blpUd3ZVM1AtdjhENHVxazgzdmIwLXFaWFVLUFROMnJHaG9SMHlRaFB1MDA0dGdBaFE3QmZIN3dSalRfOTFRMmZXQjBMekZzVUpVVjM1UnZGa0wzaXNxYVJ2UTdTN2huV1p3?oc=5","date":"2025-04-24","type":"regulatory","source":"prnewswire.com","summary":"NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update - prnewswire.com","headline":"NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnershi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQeEt0SmZFZVdKU3pEeWgyaUxMR2NVTER3eUdhVFREaHhaa3NsQktjTGNUcENyakpJY1BOV2xUTXFtV3VRQkVjMnhoVVE5NmtJSmlIYmZuQV9qU0RQMkxmcXJlanVsV2lzNnQ2bVhtTWE2Y3A1cE1Ub3RuQ3ZfUWdZQ3hJbHJtVUEtb1dZU25nUjFCYV9qX2JYZ3VxVGl0LV9jOWkwWWZfVmZJTlV6UGxwaFdERTlYaUo0akhfazJ6cWQyQmxHZzlySHNuQXBhVk9YaDBoVDQ0cWJXeEFDNGZvVmQtOA?oc=5","date":"2025-04-07","type":"pipeline","source":"prnewswire.com","summary":"NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates - prnewswire.com","headline":"NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNZFdOMERVX1FLckppdVVJWHJjM09vNjJxTmtQX21nbkNOeVc2b0xYcnRyb0ZXNF9FckZ1OExNOEtxWlhYS2dGNUVyMzJBWkVucUNKZjVINHpNaU0tZmhYREU5QTU1LW1RclcxQlB5elVjeG9BUi15NHF1R1FabEI1YmZFYmJweG1MeGtzX1Y2b3F2aVFxcS1NSnlRNG9uLUs2ejJQYzBtd1hEaUFmWFplVDNNUWVJQmNGSVhRUDQwWmdEeEJJdXl3ZmdtVQ?oc=5","date":"2024-12-23","type":"pipeline","source":"prnewswire.com","summary":"NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS - prnewswire.com","headline":"NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxNR3JCQnhRWFJKakk0Ykwxd25Za2xkR2lvY1ZPbGNUR29BaDZiaHZ5TWRZbmxUUm9RaXNPWFNjaFduVUw5NHBZRmZWQ01KYnUwNlVlRzg3UFVZcWJ4eFpzNHk1VGZLNDd4OWwzUllQRkIyZFNsVzB5UDBNd3Q3OGFMQllCR2NDczdtaXhETmhhM0swQ2oxT1NRRnlvdkRQbzRGLWFJX3BqTXRXcHQya3ctdFJEYlc0YlAwdFo0bW1TMFNTQUhSb01scmI2SFYwN3RISDhRUU9yazBLWklLMU9nbEJINGdaa3QtdTh3d0dYdHVnY3R1b2FEZDFWcGk2YkdqX25yOVVNUC1xOVRVWDVKcl80NGgwc0ZwZW9MLUJLYjFmWkl6T1NOT1hXQ1h4eVlNNTVLVU9pWDB4bFBLVUdiSEMzT0wyZ0ZVMERyTmdYanlXWGhwbGc?oc=5","date":"2024-11-13","type":"trial","source":"GlobeNewswire","summary":"NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears - GlobeNewswire","headline":"NLRP3 Protein Inhibitors Clinical Trial Pipeline Appears","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPTzRvVHlQNTJDOWJJYTVEcHZwRTFaa19GYW9Zdml0cTYwMlNtemFRTU1mWG1jZUJUc0RseFNLd2RsR0VhRFdVUDZxQ3BFSWo4aVlQanpoYjZXVUF6RGdxOWRGVThodFZrVzhpX3ZmeEJwcUE5LWV1bnR3YVVpeVBkZVlPQmI4NlVwZ211Vzd5cTR3UVZpV0trbEdjdVFpV3I3VVZJMVFqbw?oc=5","date":"2024-08-14","type":"pipeline","source":"Grand View Research","summary":"Canada Attention Deficit Hyperactivity Disorder Market Size & Outlook, 2030 - Grand View Research","headline":"Canada Attention Deficit Hyperactivity Disorder Market Size & Outlook, 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE01Z3M0cTlGVGV6WVozZmpUWXBEZERMTDRBTDlFcmJYZ09BbE9BQmhpeE9Ub1VFVm9xUW5ZdEN6aGZFMzg0eXhyYU1HMmRTWnU3OGc?oc=5","date":"2023-04-21","type":"pipeline","source":"Yahoo Finance Singapore","summary":"Nuvectis Pharma, Inc. (NVCT) stock price, news, quote and history - Yahoo Finance Singapore","headline":"Nuvectis Pharma, Inc. (NVCT) stock price, news, quote and history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE5rbXEtX28zZHpTanZvMUkwNnFmVmtKMEFaRWZqZUxnMWtXdG5NUDNlemZsczd6R3hEeUlFeGs5NW9veGdONnFQYkt1V1JPdGRha3dEalg3UDNxbWJZ?oc=5","date":"2021-12-10","type":"pipeline","source":"TradingView","summary":"NRSN Stock Price and Chart — NASDAQ:NRSN - TradingView","headline":"NRSN Stock Price and Chart — NASDAQ:NRSN","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}